Rasio utang marang kapitalisasi buku: ALX Oncology (ALXO)

ALX Oncology (ALXO) - logo korporat

ALX Oncology Holdings (ALXO) complies with environmental regulations by minimizing laboratory waste. The business is resilient to market shocks, as the success of cancer immunotherapy depends on science rather than GDP. Fluctuations in the debt-to-book capitalization ratio demonstrate the liability structure, where the value of 0.08 expresses the metric level. However, geopolitical tensions and sanctions could significantly slow down global clinical trials.

ALXO ALX Oncology: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 31.10.2026
Sampel barang ALX Oncology Holdings Inc.

For ALX Oncology Holdings (ALXO), the ratio of total liabilities to the book value of equity determines the business's degree of financial autonomy. This metric measures the proportion of borrowed funds within the equity structure to assess credit load risk. The debt-to-book capitalization trend on the GURU.Markets platform visualizes the company's resilience to external shocks. Low leverage is critical when implementing costly software automation for clinical trials, as it ensures financial stability during the digitalization of laboratory data.

Pesaing wigati

Utang-utang marang kapitalisasi buku IBRX (ImmunityBio, Inc.)|IMCR - Utang marang nilai buku|JANX - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Arcus Biosciences Inc|Zymeworks Corp (ZYME) - Rasio utang marang kapitalisasi buku|TNGX (Tango Therapeutics Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Iovance Biotherapeutics|Utang-utang marang nilai buku immatics.com IMTX|Utang-utang marang kapitalisasi buku XNCR|Compass Therapeutics Inc (CMPX) - Utang marang aset resik|Replimune Corp - Utang marang nilai buku|Lyell Pharma (LYEL) - Utang-utang marang nilai buku|IPHA: Utang marang nilai buku|Rasio utang marang aset resik PYXS (Pyxis Oncology, Inc.)|CGEN: Utang-utang marang kapitalisasi buku|IOBT - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku Sutro Bio|Utang marang nilai buku MiNK Therapeutics, Inc (INKT)|Rasio utang marang kapitalisasi buku Werewolf Therapeutics (HOWL)|Utang marang nilai buku immixbio.com IMMX|Cue Biopharma, Inc. - Utang marang nilai buku|Utang-utang marang kapitalisasi buku PDS Biotech PDSB|SONN - Rasio utang marang kapitalisasi buku|MAIA (MAIA Bio) - Rasio utang marang nilai buku|Liminatus Pharma (LIMN) - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku LAVA Therapeutics (LVTX)|Utang marang nilai buku NXTC|LPTX - Utang marang aset resik|Utang marang nilai buku INTS (Intensity Therapeutics)|Utang marang modal buku SNSE|Utang-utang marang kapitalisasi buku TOVX (Theriva Biologics, Inc.)|Rasio utang marang aset resik GRTS|Kineta - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku NexImmune Inc|turnstonebio.com (TSBX) - Rasio utang marang kapitalisasi buku|Vaccinex Inc - Rasio utang marang aset resik|HARP (Harpoon Therapeutics) - Utang-utang marang kapitalisasi buku